AI assistant
Sending…
Cartesian Therapeutics, Inc. — Director's Dealing 2022
Nov 30, 2022
33483_dirs_2022-11-30_71369d8e-0b29-4f19-b31f-d8c8d91f1e04.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2022-11-28
Reporting Person: Davis Blaine (Chief Financial Officer)
More from Cartesian Therapeutics, Inc.
Capital/Financing Update
2026
May 26
Share Issue/Capital Change
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Earnings Release
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 28
Board/Management Information
2026
Mar 30
Major Shareholding Notification
2026
Feb 5
Investor Presentation
2026
Jan 9
Director's Dealing
2026
Jan 8
Director's Dealing
2026
Jan 8